Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.72 |
| ▸ | HPGD | P15428 | 4/20 | 0.72 |
| ▸ | HTT | P42858 | 4/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.71 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | IKBKB | O14920 | 1/20 | 0.52 |
| ▸ | EEF2K | O00418 | 8/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.51 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4117084 | 0.92 | ALDH1A1 (0.72) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL4109822 | 0.88 | ALDH1A1 (0.68) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL13941637 | 0.84 | ALDH1A1 (0.96) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL429207 | 0.84 | ALDH1A1 (1.00) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL4104084 | 0.82 | ALDH1A1 (0.66) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL13991623 | 0.80 | ALDH1A1 (0.71) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL5958465 | 0.80 | ALDH1A1 (0.74) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL4117588 | 0.79 | ALDH1A1 (0.69) | ALDH1A1HPGDHTTTDP1LMNA | |
| Hydrochloric Acid SCHEMBL4104360 | 0.79 | ALDH1A1 (0.72) | ALDH1A1HPGDHTTTDP1LMNA | |
| SCHEMBL13941660 | 0.79 | ALDH1A1 (0.72) | ALDH1A1HPGDHTTTDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090029983-A1 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY | VALEANT RESEARCH & DEVELOPMENT (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029983-A1 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY | VALEANT RESEARCH & DEVELOPMENT (US) | 2009-01-29 | — | — | US | disclosed |
| US-20090029983-A1 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY | VALEANT RESEARCH & DEVELOPMENT (US) | 2009-01-29 | — | — | US | disclosed |
| US-7465742-B2 | Heterocyclic compounds having anti-HBV activity | VRX HOLDCO LLC | 2008-12-16 | — | — | US | disclosed |
| US-7465742-B2 | Heterocyclic compounds having anti-HBV activity | VRX HOLDCO LLC | 2008-12-16 | — | — | US | disclosed |
| US-20060189643-A1 | Novel heterocyclic compounds having anti-HBV activity | BAUSCH+LOMB OPS B.V. (NL) | 2006-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029983-A1 | NOVEL HETEROCYCLIC COMPOUNDS HAVING ANTI-HBV ACTIVITY | HCCS, HAVCR2, HMBS | ALDH1A1 3227/4885HPGD 58/4885HTT 4371/4885 |
| US-20060189643-A1 | Novel heterocyclic compounds having anti-HBV activity | HCCS, HAVCR2, HMBS | ALDH1A1 3227/4885HPGD 58/4885HTT 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.